From a pathophysiological point of view, KCNx channels are essential for the repolarization of the neuronal membrane and the regulation of the membrane potential. Its dysfunction can cause neuronal hyperexcitability, which results in epilepsy, episodic paralysis, ataxia, or neuropsychological development disorders. For example, mutations in KCN1<\/em> (Kv1.1) are associated with episodes of ataxia and paralysis syndrome (EA1), an autosomal dominant disorder that manifests in childhood with brief episodes of ataxia, tremors, and, in some cases, partial seizures. The KCNx Database provides not only the exact location of the mutation (for example, in the S4 transmembrane domain), but also its functional classification: whether it alters potassium permeability, activation time, inactivation or recovery. A recent study published in Nature Neuroscience<\/em> (2023) demonstrated that certain variants in KCN1<\/em> They cause a loss of function that correlates with a higher frequency of seizures in children with AD1, allowing clinicians to adjust treatment with membrane-stabilizing drugs, such as acetazolamide or lamotrigine, more precisely.<\/p>\n In the pediatric context, the KCNx Database is especially valuable in the differential diagnosis of early-onset epilepsies, autism spectrum disorders (ASD), and developmental delay syndromes with hypotonia or spasticity. For example, mutations in KCN2<\/em> (Kv2.1) have been linked to neonatal-onset epilepsy, with phenotypes including progressive encephalopathy, severe hypotonia, and heart rhythm abnormalities (associated Brugada syndrome). The database allows clinicians to compare the variant found in a patient with a set of variants of known pathogenicity, using prediction algorithms such as CADD, REVEL and PolyPhen-2, which are directly integrated into the platform. In addition, it offers access to tissue expression data in the fetal brain (according to the BrainSpan project), allowing us to evaluate whether a mutation affects a channel whose expression is critical during specific stages of brain development, such as the formation of the prefrontal cortex between weeks 12 and 20 of gestation.<\/p>\n The flow chart illustrating the main categories of information in the KCNx Database (attached figure) is not merely informative, but rather an interactive clinical guide. Each branch represents an evaluation axis: Genetics<\/strong> includes not only nucleotide sequence and variant classification (benign, probably pathogenic, pathogenic), but also frequency in controlled populations (1000 Genomes, gnomAD), inheritance (autosomal dominant, recessive, X-linked), and phenotypic penetrance. The branch Structure<\/strong> shows three-dimensional models of the channels based on X-ray crystallography and cryoelectronics, allowing us to visualize how a mutation in the potassium-binding domain (e.g., in the selection filter) can block the passage of ions. The branch Features<\/strong> includes electrical activity data obtained in heterologous expression systems, with current-voltage curves and inactivation times, which allows predicting whether a mutation causes a gain or loss of function. A typical clinical case: an 18-month-old child with partial seizures and progressive ataxia, whose exome reveals a variant in KCN13<\/em> (Kv13). Consulting the KCNx Database, it is observed that this variant is located in the S6 domain, with a 70% reduction in potassium current under stimulation conditions, confirming a loss of function. This guides the clinical team towards treatment with drugs that increase the activity of alternative potassium channels, such as retigabine (although its use in children under 2 years of age requires caution due to side effects).<\/p>\n Additionally, the KCNx Database includes a clinical correlation<\/em> which allows users to compare the patient's phenotype with other registered cases. For example, if a patient presents with neonatal hypotonia, epilepsy with onset in the first month of life, and developmental delay, the system can suggest a list of variants in KCN1<\/em>, KCN2<\/em>, KCN11<\/em> (Kv11.1, associated with Long QT syndrome type 2 and epilepsy), or KCN15<\/em> (Kv15), with a phenotypic similarity score. This functionality is especially useful in cases with difficult diagnosis, such as in patients with atypical phenotypes or rare mutations. However, it is crucial to recognize the limitations: the database does not yet include all the phenotypes described in the literature, and functional prediction does not replace experimental validation. Therefore, it is always recommended to confirm variants with functional tests in the laboratory (for example, in cellular expression systems) when the diagnosis is doubtful.<\/p>\n In short, the KCNx Database is not just a database, but an integrated clinical intelligence platform that transforms the neuropediatrician's practice. It allows a transition from genetic diagnosis towards a functional and personalized approach, aligned with the principles of precision medicine. Its systematic use in the diagnosis of pediatric neurological disorders can significantly reduce diagnostic time, avoid unnecessary tests, and guide treatment toward more effective options. To access this tool, it is recommended to visit the official portal: KCNx Database \u2013 Neuropedia Toolkit<\/a>.<\/p>","protected":false},"excerpt":{"rendered":" KCNx Databases: An Essential Tool for the Diagnosis and Management of Neurological Disorders in Childhood The KCNx Database represents one of the most advanced and specialized platforms in the field of pediatric neurogenetics, designed specifically to integrate and organize multidimensional data on potassium channels of the KCNx type (K+ channel, voltage-gated, subfamily... <\/p>\n![\"Diagrama](\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2025\/12\/image.png\")